

Recombinant Human IL-1 β (carrier-free)

Catalog # / Size: 579402 / 10 μ g
579404 / 25 μ g
579406 / 100 μ g
579408 / 500 μ g

Source: Human IL-1 β , amino acids Ala117-Ser269 (Accession # NM_000576) was expressed in *E. coli*.

Molecular Mass: The 153 amino acid recombinant protein has a predicted molecular mass of 17,376 Da. The DTT-reduced and the non-reduced protein migrate at approximately 18kDa by SDS-PAGE. The N-terminal amino acid is Alanine.

Purity: Purity is >98%, as determined by Coomassie stained SDS-PAGE.

Endotoxin Level: Endotoxin level is <0.1 EU/ μ g (<0.01ng/ μ g) protein as determined by the LAL method.

Activity: The ED₅₀ is 0.858-1.85 μ g/ml, corresponding to a specific activity of 1.16-0.54 x 10⁹ units/mg, as determined by the dose dependent stimulation of D10 cells proliferation.

Preparation: 10-100 μ g sizes are bottled at 200 μ g/mL, 500 μ g sizes and larger are bottled at the concentration indicated on the vial.

Formulation: 0.22 μ m filtered protein solution is in 10mM NaH₂PO₄, 150mM NaCl, pH 7.2.

Storage: Unopened vial can be stored at 4°C for three months, at -20°C for six months, or at -70°C for one year. For maximum results, quick spin vial prior to opening. Stock solutions should be prepared at no less than 10 μ g/mL in buffer containing carrier protein such as 1% BSA or HSA or 10% FBS. For long term storage, aliquot into polypropylene vials and store in a manual defrost freezer. **Avoid repeated freeze/thaw cycles.**

Applications:

Applications: Bioassay

Recommended Usage: Use when high specific biological activity is required.

Application Notes: This IL-1 β protein is biologically active, and can be used for in vitro assays

Description: IL-1 β in humans and mice does not encode a typical signal peptide and, as a result, newly synthesized pro-IL-1 β accumulates within the cytoplasm of activated monocytes and macrophages (1). Conversion of the inactive pro-IL-1 β to its mature form requires the proteolytic action of IL-1 β -converting enzyme (ICE), also termed caspase-1 (2). Secretion of mature IL-1 β from LPS-activated monocytes/macrophages is not a constitutive process. These cells must encounter a secondary stimulus that specifically activates the posttranslational processing events (2). Moreover, owing to its pro-inflammatory nature, IL-1 β is regarded as a tumor-promoting cytokine. In fact, enhanced tumor metastasis and angiogenesis has been observed under the influence of IL-1 β (3). IL-1 β is able to facilitate tumor progression in murine models of lung cancer. In addition, upregulation of metastasis and tumor angiogenesis by IL-1 β has been associated with increased activity of matrix metalloproteinases and expression of the pro-angiogenic molecule hepatocyte growth factor (4).

Antigen References: 1. Stevenson FT, *et al. J Cell Physiol* 152:223-231 1992.
2. Shi J, *et al. J. Immunol.* 179:1245-1253 2007.
3. Dinarello CA *Cancer Metastasis Rev* 25:307-313 2006.
4. Boost KM, *et al. BMC Cancer* 8:265 2008.



For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.



*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.